-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
Recent News
-
Pride Month: Honoring identity and celebrating diversity
This Pride Month, let us lead with kindness and celebrate the vibrant spectrum of human identity that enriches our work as clinicians.
-
Shared decision-making in PAH
Shared decision-making is a collaborative process where clinicians and patients make informed health care decisions together, balancing medical evidence with patient values, which is especially important in complex conditions like PAH.
-
Opening the flood gates: Pleural complications of immune checkpoint inhibitors
The pulmonary and medical oncology community must start to consider pleural complications as a potential risk of immune checkpoint inhibitor therapy.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Advanced practice respiratory therapist: The new advanced practice provider
The rise of the advanced practice respiratory therapist marks a pivotal advancement in respiratory care, addressing the growing need for specialized providers in health care.